Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly,

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.